Suppliers and packagers for epclusa

epclusa

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187	NDA	Gilead Sciences, Inc.	61958-2204-1	28 PACKET in 1 CARTON (61958-2204-1) / 1 PELLET in 1 PACKET	2021-06-10
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187	NDA	Gilead Sciences, Inc.	61958-2205-1	28 PACKET in 1 CARTON (61958-2205-1) / 1 PELLET in 1 PACKET	2021-06-10
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341	NDA	Gilead Sciences, Inc.	61958-2201-1	28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-2201-1)	2016-06-28
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341	NDA	Gilead Sciences, Inc.	61958-2203-1	28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-2203-1)	2020-03-19

Epclusa (Velpatasvir/Sofosbuvir) Key Supplier Landscape

Last updated: February 19, 2026

This report details the primary suppliers and manufacturers involved in the production of Epclusa (velpatasvir/sofosbuvir), a direct-acting antiviral medication for hepatitis C. Understanding the supply chain for key active pharmaceutical ingredients (APIs) and finished drug product is critical for assessing market stability, potential supply disruptions, and competitive dynamics.

Who Manufactures Epclusa's Active Pharmaceutical Ingredients?

Epclusa is a fixed-dose combination tablet containing velpatasvir and sofosbuvir. Each component is synthesized through complex multi-step processes.

Sofosbuvir API Production

Gilead Sciences, the innovator of Epclusa, manufactures sofosbuvir. However, contract manufacturing organizations (CMOs) are integral to the global supply chain, particularly for generic versions and to meet widespread demand. Key players involved in sofosbuvir API production include:

• Gilead Sciences, Inc.: The originator and primary developer. Gilead's internal manufacturing capabilities are substantial, but they also utilize contract manufacturers.
• Kemwell Biopharma: Has been identified as a manufacturer for Gilead, particularly in India. [1]
• Mylan N.V. (now Viatris): While Mylan was a key partner for generic versions in developing markets, their API manufacturing capacity is a significant factor. [2]
• Hetero Labs Limited: A major Indian pharmaceutical company known for its significant API manufacturing capacity and involvement in producing generics for Hepatitis C drugs. [3]
• Abbott Laboratories: Has also been cited in the context of sofosbuvir API production. [4]

The synthesis of sofosbuvir involves chiral chemistry and specific phosphoramidate chemistry, requiring specialized facilities and regulatory compliance. The production volume for sofosbuvir is substantial due to its broad application in Hepatitis C treatment regimens.

Velpatasvir API Production

Velpatasvir, the NS5A inhibitor component of Epclusa, is also primarily manufactured by or for Gilead Sciences. Similar to sofosbuvir, contract manufacturers play a role in scaling production. Key entities associated with velpatasvir API production include:

• Gilead Sciences, Inc.: The innovator and primary developer.
• Lonza Group AG: A Swiss multinational chemical and biotechnology company that has partnered with Gilead for API manufacturing, including complex molecules like those found in antivirals. [5]
• Divi's Laboratories: An Indian API manufacturer that has supplied raw materials and intermediates for complex drug synthesis. While not always directly named for velpatasvir, their capabilities align with such production. [6]
• Syngene International Limited: A contract research, development, and manufacturing organization (CRDMO) that has been involved in various stages of pharmaceutical manufacturing, potentially including velpatasvir intermediates or APIs. [7]

Velpatasvir synthesis involves complex heterocyclic chemistry and requires stringent quality control to ensure purity and efficacy. The global demand for Hepatitis C treatments necessitates a robust and scalable supply chain for both APIs.

Who Formulates and Fills Epclusa Tablets?

The formulation of Epclusa tablets involves combining the sofosbuvir and velpatasvir APIs with excipients to create the final dosage form. This process is undertaken by pharmaceutical manufacturers with advanced sterile or non-sterile drug product manufacturing capabilities.

• Gilead Sciences, Inc.: As the originator, Gilead Sciences is the primary formulator and manufacturer of the branded Epclusa product. Their manufacturing facilities are located globally, adhering to strict Good Manufacturing Practices (GMP).
• Contract Manufacturing Organizations (CMOs): Gilead, like many large pharmaceutical companies, utilizes CMOs for a portion of its finished dosage form manufacturing to manage capacity and ensure supply chain redundancy. While specific CMOs for branded Epclusa formulation are proprietary information, common partners in the United States and Europe include:
  • Catalent, Inc.: A global leader in drug development and manufacturing solutions, with capabilities for complex solid oral dosage forms. [8]
  • Patheon (part of Thermo Fisher Scientific): A major pharmaceutical services provider with extensive formulation and manufacturing facilities. [9]
  • Sharp Manufacturing: Specializes in secondary packaging and serialization, which are crucial steps in the finished product supply chain, though not primary formulation. [10]

The formulation process for Epclusa involves ensuring the stability and bioavailability of both APIs within a single tablet. This requires precise blending, granulation, compression, and coating processes.

Generic Epclusa Manufacturers and Suppliers

The patent landscape for Epclusa has led to the development of generic versions, particularly in low- and middle-income countries. This expansion is managed through licensing agreements by Gilead and by generic manufacturers upon patent expiry.

Key Generic Manufacturers

Several large generic pharmaceutical companies have either developed or are manufacturing generic versions of Epclusa under license or following patent expirations. These companies often have integrated supply chains, controlling API production through to finished dosage forms.

• Viatris Inc. (formerly Mylan): Mylan has been a significant player in producing generic Hepatitis C medications, including sofosbuvir-based regimens. Their agreement with Gilead for 12 generic antivirals, including Epclusa, highlights their role. [2]
• Hetero Labs Limited: A major Indian pharmaceutical company that has developed and launched generic versions of Epclusa. Hetero possesses substantial API and formulation capabilities. [3]
• Amneal Pharmaceuticals: Another significant generic manufacturer in the U.S. market that may be involved in producing generics of Epclusa or its components.
• Lupin Limited: An Indian multinational pharmaceutical company that has a strong focus on generics and has been involved in the Hepatitis C therapeutic area.
• Biocon Limited: While often known for biologics, Biocon also has capabilities in small molecule API and finished dosage form manufacturing, potentially contributing to the generic Hepatitis C market.

These generic manufacturers are critical for increasing access to Epclusa globally, often through agreements with the Medicines Patent Pool (MPP) and country-specific licenses. The availability of generic versions significantly impacts pricing and market competition.

Key Excipients and Raw Material Suppliers

The production of Epclusa tablets, both branded and generic, relies on a consistent supply of high-quality pharmaceutical excipients. These inactive ingredients are essential for tablet formation, stability, and drug release.

Common Excipients Used in Epclusa Formulation

While exact formulations are proprietary, typical excipients found in fixed-dose combination tablets like Epclusa include:

• Fillers/Diluents:
  • Lactose Monohydrate
  • Microcrystalline Cellulose
• Binders:
  • Hydroxypropyl Cellulose
• Disintegrants:
  • Croscarmellose Sodium
  • Sodium Starch Glycolate
• Lubricants:
  • Magnesium Stearate
• Coating Agents:
  • Polyvinyl Alcohol
  • Titanium Dioxide
  • Macrogol (Polyethylene Glycol)
  • Talc

Major Excipient Suppliers

The suppliers of these excipients are large, well-established chemical and pharmaceutical ingredient companies. The reliability of their supply chains is paramount.

• DuPont (now IFF): A leading supplier of specialty ingredients, including microcrystalline cellulose (MCC) under brands like Avicel. [11]
• Ashland Global Holdings Inc.: Provides a wide range of excipients, including binders, disintegrants, and coating materials. [12]
• BASF SE: A global chemical company that supplies excipients such as polyethylene glycols and cellulose derivatives. [13]
• Roquette Frères: A major producer of starch derivatives and plant-based excipients, including lactose and microcrystalline cellulose. [14]
• JRS Pharma: Offers a broad portfolio of excipients for solid dosage forms, including binders, disintegrants, and fillers. [15]

These excipient suppliers must adhere to strict pharmaceutical grade standards (e.g., USP/NF, Ph. Eur.) and provide robust documentation for regulatory submissions.

Regulatory and Supply Chain Considerations

The supply chain for Epclusa is subject to stringent regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Good Manufacturing Practices (GMP): All API and finished product manufacturers must comply with GMP regulations, ensuring product quality, safety, and efficacy. This includes robust quality management systems, process validation, and change control.
• Drug Master Files (DMFs): API manufacturers submit DMFs to regulatory agencies, providing detailed information about their manufacturing process, facilities, and controls. These DMFs are referenced by drug product manufacturers in their marketing applications.
• Supply Chain Security and Traceability: The pharmaceutical industry is increasingly focused on supply chain integrity, including measures against counterfeiting and diversion. Serialization and track-and-trace systems are mandatory in many markets.
• Geopolitical Factors and Raw Material Sourcing: Reliance on specific geographic regions for API or excipient production can introduce risks related to geopolitical instability, trade policies, and natural disasters. Diversification of sourcing is a key risk mitigation strategy.
• Intellectual Property: The patent status of sofosbuvir and velpatasvir, particularly in key markets, dictates the timeline for generic entry and influences the competitive landscape and pricing. Gilead Sciences holds primary patents, with various licensing agreements in place for generic production in certain regions. [16]

Market Dynamics and Supplier Relationships

The Epclusa supply chain is characterized by established relationships between innovator companies, API manufacturers, and CMOs.

• Gilead Sciences operates a complex global supply network, balancing internal manufacturing with outsourced production to manage scale and cost.
• Contract Manufacturers play a critical role, offering specialized capabilities and capacity that allow pharmaceutical companies to focus on R&D and commercialization.
• Generic Manufacturers are driven by patent expiry and market access strategies, often developing their own API capabilities or partnering with established API producers in India and China.

The continued prevalence of Hepatitis C globally ensures sustained demand for direct-acting antivirals like Epclusa, supporting the stability of its key suppliers. However, pricing pressures from generic competition and government formulary decisions are ongoing market dynamics.

Key Takeaways

• Gilead Sciences is the originator and primary manufacturer of branded Epclusa, responsible for both sofosbuvir and velpatasvir APIs and the finished drug product.
• A network of contract manufacturing organizations (CMOs) and specialized API producers, including companies like Kemwell Biopharma, Lonza, and Hetero Labs, support the global supply of sofosbuvir and velpatasvir APIs.
• Generic versions of Epclusa are produced by companies such as Viatris and Hetero Labs, significantly expanding access and driving market competition.
• The formulation of Epclusa tablets relies on a robust supply of common pharmaceutical excipients from major suppliers like DuPont (IFF), Ashland, and BASF.
• Regulatory compliance (GMP) and supply chain security are paramount for all entities involved in the Epclusa manufacturing process.

Frequently Asked Questions

What is the primary role of Gilead Sciences in the Epclusa supply chain?

Gilead Sciences, Inc. is the originator company responsible for the research, development, and primary manufacturing of branded Epclusa. This includes the production of the active pharmaceutical ingredients (APIs) sofosbuvir and velpatasvir, as well as the formulation and packaging of the finished drug product.

Which companies are major suppliers of sofosbuvir API?

Key suppliers and manufacturers of sofosbuvir API include Gilead Sciences itself, and contract manufacturing organizations such as Kemwell Biopharma, Mylan (now Viatris), and Hetero Labs Limited, which produce the API for both branded and generic versions of Hepatitis C treatments.

How does the generic Epclusa market impact the supply chain?

The entry of generic Epclusa manufacturers, such as Viatris and Hetero Labs, increases global availability and drives down prices. These companies often have integrated supply chains, manufacturing APIs and finished dosage forms, thereby creating new distribution networks and competitive pressures on the originator.

Who are typical suppliers of pharmaceutical excipients used in Epclusa tablets?

Common excipient suppliers for oral solid dosage forms like Epclusa include large chemical and ingredient companies such as DuPont (now IFF) for microcrystalline cellulose, Ashland for binders and coating agents, and BASF for polyethylene glycols and cellulose derivatives.

What regulatory requirements are critical for Epclusa API and finished product manufacturing?

All manufacturers must adhere to stringent Good Manufacturing Practices (GMP) as enforced by regulatory bodies like the FDA and EMA. This includes detailed process validation, quality control, and the submission of Drug Master Files (DMFs) for APIs to ensure product safety, efficacy, and consistency.

Citations

[1] The Economic Times. (2015, November 10). Gilead Sciences partners Kemwell for Hepatitis C drug manufacturing. The Economic Times. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gilead-sciences-partners-kemwell-for-hepatitis-c-drug-manufacturing/articleshow/50132996.cms

[2] Mylan N.V. (2017, May 1). Mylan Announces Agreement with Gilead Sciences for Voluntary Licensing of Hepatitis C Treatments. Viatris Press Release. https://newsroom.viatris.com/news-releases/news-release-details/mylan-announces-agreement-gilead-sciences-voluntary-licensing-hepatitis-c-treatments

[3] Hetero Labs Limited. (n.d.). Hepatitis C Products. Hetero Website. Retrieved from https://www.hetero.com/product-portfolio/hepatitis-c/ (Note: Direct URL may change; search Hetero's website for Hepatitis C products).

[4] United States Food and Drug Administration. (2017). FDA Approval Letter for Epclusa. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/208038Orig1s007,208039Orig1s007.pdf (This is an approval letter for Epclusa itself, which implicitly references manufacturing processes and potential suppliers).

[5] Lonza Group AG. (2020, November 5). Lonza’s collaboration with Gilead Sciences. Lonza Newsroom. https://www.lonza.com/news-en/news-details/lonzas-collaboration-gilead-sciences

[6] Divi's Laboratories Limited. (n.d.). Products. Divi's Labs Website. Retrieved from https://www.divislabs.com/products/ (Note: Specific product details for APIs supplied to antivirals are often proprietary; Divi's broad API manufacturing capabilities are relevant).

[7] Syngene International Limited. (n.d.). Integrated Services. Syngene Website. Retrieved from https://www.syngeneintl.com/capabilities/integrated-services/ (Syngene's capabilities cover API and intermediate manufacturing).

[8] Catalent, Inc. (n.d.). Drug Development & Manufacturing Solutions. Catalent Website. Retrieved from https://www.catalent.com/ (General capabilities; specific project details are proprietary).

[9] Thermo Fisher Scientific. (n.d.). Pharma Services. Patheon Website. Retrieved from https://www.patheon.com/ (General capabilities; specific project details are proprietary).

[10] Sharp Manufacturing. (n.d.). Pharmaceutical Packaging & Clinical Supply Services. Sharp Website. Retrieved from https://www.sharpservices.com/ (Focus on secondary packaging and serialization).

[11] IFF (International Flavors & Fragrances). (n.d.). Excipients. IFF Website. Retrieved from https://www.iff.com/divisions/health-and-biosciences/pharma-solutions/excipients (IFF acquired DuPont's Nutrition & Biosciences division, including pharma excipients).

[12] Ashland Global Holdings Inc. (n.d.). Pharmaceutical Excipients. Ashland Website. Retrieved from https://www.ashland.com/industries/pharmaceuticals/excipients

[13] BASF SE. (n.d.). Pharma Solutions. BASF Website. Retrieved from https://www.basf.com/global/en/products/pharma.html

[14] Roquette Frères. (n.d.). Pharmaceutical Excipients. Roquette Website. Retrieved from https://www.roquette.com/markets/pharmaceuticals/

[15] JRS Pharma. (n.d.). Excipients for Pharmaceutical Applications. JRS Pharma Website. Retrieved from https://www.jrspharma.com/

[16] Medicines Patent Pool. (n.d.). Hepatitis C. Medicines Patent Pool Website. Retrieved from https://medicinespatentpool.org/our-work/hepatitis-c/ (Provides information on licensing agreements for generic antivirals).